Dongbao Pharma's diabetes drug shows promise in trial

Tonghua Dongbao Pharmaceutical announced positive results from a Phase Ib clinical trial of its GLP-1/GIP dual-target receptor agonist, THDBH120, for the treatment of type 2 diabetes. The trial, conducted by its subsidiary Dongbao Zixing (Hangzhou) Biomedical, achieved its primary endpoint, demonstrating favorable safety, tolerability, and efficacy. Key findings include significant HbA1c reduction, even at low doses, compared to existing treatments. Dongbao has invested approximately RMB 100.27 million in the project to date. The company noted the drug's potential to become a longer-acting treatment option for diabetes, positioning it against competitors like Eli Lilly's Tirzepatide (Mounjaro/Zepbound). Further clinical trials are planned.